drugset
drugset / Trial / NCT03970746

Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

NCT03970746 ↗

Phase 1/2 Active not recruiting 73 enrolled PDC*line Pharma SAS
Non-randomizedSequentialOpen-labelTreatment

Summary

PDC-LUNG-101 trial is an open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC\*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer.

Timeline

Start
2019-09-10
Primary completion
2024-07-18
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PDC*lung01 Vaccine — Subcutaneous
Background Pembrolizumab Monoclonal antibody — —
Background Pemetrexed Small molecule — Intravenous

Indications

non-small cell lung carcinoma